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Abstract
Background: Probe based detection assays form the mainstay of transcript quantification. Problems with these assays
include varying hybridization efficiencies of the probes used for transcript quantification and the expense involved. We
examined the ability of a standardized competitive RT-PCR (StaRT PCR) assay to quantify transcripts of 4 cell cycle
associated genes (RB, E2F1, CDKN2A and PCNA) in two cell lines (T24 & LD419) and compared its efficacy with the
established Taqman real time quantitative RT-PCR assay. We also assessed the sensitivity, reproducibility and consistency
of StaRT PCR. StaRT PCR assay is based on the incorporation of competitive templates (CT) in precisely standardized
quantities along with the native template (NT) in a PCR reaction. This enables transcript quantification by comparing the
NT and CT band intensities at the end of the PCR amplification. The CT serves as an ideal internal control. The transcript
numbers are expressed as copies per million transcripts of a control gene such as β-actin (ACTB).
Results: The NT and CT were amplified at remarkably similar rates throughout the StaRT PCR amplification cycles, and
the coefficient of variation was least (<3.8%) when the NT/CT ratio was kept as close to 1:1 as possible. The variability
between the rates of amplification in different tubes subjected to the same StaRT PCR reaction was very low and within
the range of experimental noise. Further, StaRT PCR was sensitive enough to detect variations as low as 10% in
endogenous actin transcript quantity (p < 0.01 by the paired student's t-test). StaRT PCR correlated well with Taqman
real time RT-PCR assay in terms of transcript quantification efficacy (p < 0.01 for all 4 genes by the Spearman Rank
correlation method) and the ability to discriminate between cell types and confluence patterns.
Conclusion: StaRT PCR is thus a reliable and sensitive technique that can be applied to medium-high throughput
quantitative transcript measurement. Further, it correlates well with Taqman real time PCR in terms of quantitative and
discriminatory ability. This label-free, inexpensive technique may provide the ability to generate prognostically important
molecular signatures unique to individual tumors and may enable identification of novel therapeutic targets.
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Background
Molecular definition of tumors can be achieved at the
genomic, transcriptomic or proteomic level. Morphologi-
cally similar tumors are often prognostically distinct and
the different clinical outcomes are due to differences in
biology. Molecular pathology is therefore rapidly evolving
to include characterization of unique molecular patterns
in tumors. While genomic changes are crucial in the initial
stages of a disease, dynamic alterations in the expression
of these genes at mRNA and protein levels determine the
disease progression. As the evidence for involvement of
intricate molecular pathways in disease progression con-
tinues to rapidly accumulate, relational transcript quanti-
fication for coordinately linked genes will provide a novel
tool for tumor characterization. These transcript varia-
tions can be characterized as fluctuations in expression of
a given gene across many tumors (expression profile) or
changes in expression of many genes in the same tumor
(expression signature) [1]. A number of methods are availa-
ble for quantitative transcript measurement, including
cDNA microarrays and real time RT-PCR. Until recently,
however, there was no method available that could easily
be subjected to quality control, which is critical for clinical
diagnostic and pharmaceutical industry applications. Fur-
ther, all previously available methods were limited to gen-
erating a 'profile', and not fine-tuned for assigning a
molecular 'signature', because they did not control for dif-
ferences in efficiency of hybridization for different gene
probes with their corresponding cDNA. In contrast, com-
petitive RT-PCR has the capability to achieve hybridiza-
tion-independent transcript quantification through the
incorporation of internal competitors nearly identical to
the native cDNA templates in the reaction mixture. This
technique has received only limited attention in the past
few years because of the lack of standardization. Recently,
however, this technique has been standardized by design-
ing and incorporating competitors at precise copy num-
bers for all individual genes to be quantified [2]. The
competitive templates thus provide the internal standards
and allow end point PCR quantification. The Standard-
ized RT-PCR (StaRT PCR) technique quantifies transcripts
by comparing the NT and CT band intensities at the end
of the PCR amplification and the transcript numbers are
expressed as copy numbers per million molecules of a
housekeeping gene such as β-actin. Further, StaRT PCR
has the ability to reliably quantify variations in expression
of different genes, as long as internal standards and
endogenous targets amplify with identical efficiency.
StaRT PCR is thus capable of generating both molecular
profiles and signatures, is relatively inexpensive, and has
the potential to develop into a high-throughput assay sys-
tem for transcript quantification [2].
In this paper, we have examined the ability of StaRT PCR
to quantify transcripts of 4 cell cycle-associated genes (RB,
E2F1, CDKN2A and PCNA) in two cell lines and com-
pared it with the established real time RT-PCR assay. Two
different bladder tissue-derived cell lines were used – T24
(an established commercially available urothelial carci-
noma cell line) and LD419 (a primary culture fibroblastic
cell line). Further, we demonstrate the sensitivity, repro-
ducibility and consistency of this technology, testing for
variables such as cell type, culture confluence and starting
total RNA amount.
Results
Linearity of Amplification
When the observed NT/CT ratio for each assigned NT/CT
ratio was plotted against the number of cycles when
amplification was terminated, the NT/CT ratio was found
to remain relatively constant regardless of the amplifica-
tion end point (figure 1), indicating that the NT & CT were
amplified at a comparable rate throughout the exponen-
tial phase of Start PCR amplification process.
For each designed NT/CT ratio, coefficients of variation
(CV) between the initial ACTB transcript numbers in the
NT were calculated from the observed NT/CT ratios at the
end of StaRT PCR amplification. CV between the esti-
mated ACTB transcript numbers at the different NT/CT
ratios was found to be the least (3.8%) when the ratio was
kept close to 1. (Table 1) The CV between the estimated
ACTB transcript numbers was fairly low (<16%) over a
wide range of NT/CT ratios (0.1 to 10.0). The results were
comparable for similar experiments performed for the 3
other genes analyzed in this study (RB1, E2F1, and PCNA
– data not shown), except for CDKN2A, where it was not
possible to calculate the CV since the expression levels
were too low to be detected by gel electrophoresis until
cycle number 32.
Inter-sample variability
ACTB transcripts (from LD 419 cDNA), amplified in mul-
tiple tubes simultaneously, were quantified separately in
the PCR reactions terminated at cycles 20, 23, 26, 29, 32
& 35, and the variability between the values obtained
from the multiple tubes were compared. The variability
(coefficients of variation) between the transcript numbers
from the multiple tubes ranged from 0.70% to 5.28%,
and was within the range of inter-assay variability
observed by real time RT-PCR method [4]. (Table 2)
Ability of StaRT PCR to quantify small changes in gene 
expression
NT/CT ratios were designed to test the ability of StaRT
PCR to quantify minute changes in gene expression. The
ability of the assay system to detect changes in the amount
of the native template between consecutive NT/CT ratios
was assessed using the paired student's t-test. StaRT PCRMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/5
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Determination of linearity of NT/CT ratios over PCR cycles from 23–35 Figure 1
Determination of linearity of NT/CT ratios over PCR cycles from 23–35: LD419 cDNA was mixed with the CT to 
arrive at NT/CT ratios: 0.1, 0.5, 1, 5, and 10. Independently, each of these 5 initial NT/CT ratios were used to set up separate 
reactions, which were then subjected to PCR amplification with ACTB primers and terminated at cycles 23, 26, 29, 32, 35. All 
experiments were performed in triplicate. The mean observed NT/CT ratios (following quantification using Bio-Rad Quantity 
One software) at each end point were plotted against the cycle numbers at which the reactions were terminated. The 
observed NT/CT ratios remain significantly constant during the StaRT PCR amplification cycle when the assigned NT/CT ratio 
is close to 1.
Table 1: Determination of Coefficients of Variation (CV) to examine variability in transcript numbers for different NT/CT ratios: The 
CV between the initial ACTB transcript number in the NT was calculated based on the observed NT/CT ratios at the end of StaRT PCR 
amplification. LD419 cDNA was mixed with CT to obtain assigned NT/CT ratios: 0.1, 0.5, 1, 5, and 10. Independently, each of these 5 
assigned NT/CT ratios was used to set up separate reactions, which were subjected to PCR amplification. All experiments were 
performed in triplicate. The initial number of ACTB transcripts at each assigned NT/CT ratio was calculated at the end of the StaRT 
PCR amplification. CV between the calculated ACTB transcript numbers at the different NT/CT ratios was found to be the least when 
the ratio was kept close to 1. Further, the CV between the calculated ACTB transcript numbers was fairly low over a wide range of NT/
CT ratios.
Assigned Actin NT/CT Ratio Mean Observed Actin NT/CT Ratio Coefficient of Variation (= 100% × s.d./mean)
0.1 0.101 15.8%
0.5 0.614 9.3%
1.0 1.01 3.8%
5.0 4.68 13.4%
10.0 9.23 8.7%Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/5
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was sensitive enough to detect even the least tested change
(7%) in the transcript amount (figure 2, p < 0.01).
Furthermore, although they represent different ranges of
ACTB transcript estimates, both LD419 and T24 titration
curves have identical slopes, indicating the consistency of
the technique to quantify transcripts, regardless of differ-
ent starting transcript numbers. A linear regression analy-
sis was used to summarize and evaluate the relationship
between the serial NT/CT ratios and the number of tran-
scripts estimated. In an analysis of variance, lack of linear-
ity was tested using the lack-of-fit sums of squares. The
error sum of squares with the dilutions (11 levels) was
subtracted from the error sum of squares for the simple
linear regression model and this was compared to the
error sum of squares in the analysis of variance. Upon
analyzing for the T24 and LD419 cell lines separately, the
slope of the fitted line was used to estimate the average
increase in number of transcripts per unit change in the
NT/CT ratio (figure 2). Using the simple linear regression,
we estimated that for every 0.1 unit of increase in the "NT/
CT ratio (e.g., from 0.8 to 0.9 or from 1.1 to 1.2), the
number of β-actin transcripts in the T24 cell line increased
on average by 39,062 +/- 1,412, and for the LD419 cell
line, on average by 55,656 +/- 1,491. While the examina-
tion of the plots, suggested that the plot for LD419 was
not truly linear towards the ends (figure 2, p < 0.001 for
LD419, as compared to p = 0.14 for T24), the patterns
were consistently linear for the central part (for NT/CT
ratios from 0.7 to 1.3), (p = 0.41 for LD419 and p = 0.64
for T24) and almost uniform increases in the number of
transcripts were estimated. Thus, for every 0.1 increase in
the NT/CT ratio, the average number of β-actin transcripts
increased by 34,076 +/- 2,095 for the T24 cell line and by
48,871 +/- 2,466 for the LD419 cell line. This fairly uni-
form increment in the transcript number estimation
between the consecutive NT/CT ratios indicates that the
quantification faithfully followed the serial NT/CT titra-
tions. This also demonstrates the ability of StaRT PCR to
accurately and reliably detect changes in transcript quan-
tity as low as 7%.
Correlation between Start PCR and real time PCR
While StaRT PCR quantifies gene expression as the abso-
lute number of target transcripts per million ACTB tran-
scripts using end point analysis, real time PCR uses an
exponential phase measurement to quantify target gene
expression using the normalized reporter fluorescence
intensity of the target transcript at a threshold cycle
number (Ct). The values for the numbers of transcripts
were log transformed prior to the analysis to correct for
heteroscedasticity. Due to the intrinsic differences in the
assay systems, scatter plots of the ranked values and the
Spearman rank correlation coefficient were used to com-
pare the two methods. The transcript numbers for each
gene quantified by both methods at the chosen experi-
mental conditions (2 cell lines, 2 confluence levels, 3 ini-
tial RNA amounts-all in triplicate, a total of 36 values)
were ranked by relative transcript abundance and com-
pared. Fisher's z-transformation of the correlation coeffi-
cient was used to construct 95% confidence intervals for
the correlation coefficient. The Spearman rank correlation
data (Table 3) demonstrates that the two methods
resulted in comparable rankings for expression for each of
the four genes.
Discriminatory analysis showed that both assay systems
were equally capable of discriminating between the two
cell lines based on the expression level of the four chosen
genes (Table 4). Further, confluence patterns contributed
to a definite stratification of expression values of some of
the chosen genes by either method.
Results of the F-test showed that, confluence contributed
to stratifying the Rb gene expression levels in both cell
lines as detected by StaRT PCR, while real time PCR could
not detect this effect. Real time PCR data, however, indi-
cated confluence to be a factor stratifying E2F1 gene
Table 2: Comparison of inter-tube variability in transcript quantification: ACTB transcripts were amplified in multiple tubes 
simultaneously and the PCR reactions terminated at cycles 20, 23, 26, 29, 32 & 35. Experiments were performed in triplicate. The ACTB 
transcript number in all tubes was quantified separately at the designated end points and the variability between the values obtained 
from the multiple tubes compared. There is very little variation between the transcript numbers obtained from the multiple tubes at 
each end point.
Number of cycles of amplification Mean transcript number from 3 tubes Standard deviation Coefficient of variation
20 150369 3012.87 2%
23 144224 3047.39 2.11%
26 139305 7354.84 5.28%
29 135205 996.66 0.70%
32 135138 2175.03 1.61%
35 135413 2797.04 2%Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/5
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Ability of StaRT PCR to detect minute variations in transcript amounts Figure 2
Ability of StaRT PCR to detect minute variations in transcript amounts. NT/CT ratios were designed to test the 
ability of StaRT PCR to detect minute changes in transcript quantity. cDNAs from LD419 and T24 cells were normalized using 
ACTB primers. The starting cDNA concentrations used for this experiment were different for T24 (equivalence point) and 
LD419 (approximately 1.5 × equivalence point). NT volumes decreasing successively by 0.4 µL were mixed with a constant vol-
ume of CT (4 µL of 10–12 M ACTB) to obtain NT/CT ratios over a range of 1.5:1 to 0.5:1. This allowed us to test the sensitiv-
ity of StaRT PCR over a range of 7%–15%. These reaction mixes were then subjected to StaRT PCR amplification using ACTB 
primers and the corresponding number of ACTB transcripts in the NT was calculated. The absolute number of ACTB tran-
scripts quantified at each NT/CT ratio was plotted against the NT/CT ratio. StaRT PCR was sensitive enough to detect even 
the least tested change (7%) in the transcript amount (p < 0.01 using the paired Student's t-test).Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/5
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expression level in T24 cell line, but not in LD419 cells;
such an effect was not seen with StaRT PCR data. PCNA
transcript levels were significantly stratified by confluence
in the T24 cells by both assays, but this effect is more
markedly seen with StaRT PCR (Table 4). Both assays con-
firmed that differences in the starting RNA amount did
not alter the quantification of transcripts relative to each
other.
Discussion
This study confirms that StaRT PCR is a reliable and sensi-
tive technique that can be applied to medium-high
throughput quantitative transcript measurement for bio-
logical and clinical samples. We first verified that the
endogenous target and competitor were amplified in a lin-
ear fashion throughout the StaRT PCR amplification cycle.
Further, the CV between the calculated transcript numbers
of the endogenous target was fairly low over a wide range
of NT/CT ratios. We demonstrated that for the same
endogenous target simultaneously amplified in multiple
tubes by StaRT PCR assay, the variability between tran-
script numbers is very low and within the range of accept-
able experimental noise. Additionally, StaRT PCR is
sensitive enough to detect changes as little as 7% in
endogenous target amount. StaRT PCR also compared
well with the TaqMan quantitative real time PCR method
in transcript quantification efficacy, thereby suggesting its
use as an accurate, inexpensive, hybridization-independ-
ent alternative.
Competitive RT-PCR has evolved as a reliable strategy for
quantification of gene transcripts of interest. This method
has recently been standardized by mixing the defined
amounts of competitors for multiple cDNAs as CT mixes
in common solutions, and by generating those mixes at
competitor concentrations ranging from 10-11M to 10-
16M, covering a whole dynamic range of 6 logs of gene
expression [2]. Standardized competitive RT-PCR (StaRT
PCR) technique thus represents the first approach capable
of studying the stoichiometric relationship between the
abundance of multiple transcripts within the same sam-
ple. StaRT PCR provides an inexpensive platform for tran-
Table 3: Comparison between the transcript quantification efficiencies of StaRT-PCR and Real Time PCR: Due to the intrinsic 
differences between the two techniques of transcript quantification, the Spearman rank correlation method was used to compare the 
transcript quantification efficiencies for the two methods. The transcript numbers for each gene quantified by both methods at the 
chosen experimental conditions (2 cell lines, 2 confluence levels, 3 initial RNA amounts-all in triplicate, a total of 36 values) were ranked 
by relative transcript abundance and compared. p values <0.05 are considered significant. High correlation between both methods was 
observed.
Spearman correlation between StaRT-PCR and Real Time PCR methods with 95% CI
Markers Correlation 95% CI* p value
Rb 0.679 (0.451–0.824) <0.01
E2F1 0.707 (0.493–0.840) <0.01
p16 0.781 (0.609–0.883) <0.01
PCNA 0.829 (0.688–0.910) <0.01
*Based on Fisher's transformation of the correlation coefficient
Table 4: Comparison between StaRT PCR and Real Time PCR techniques for their discriminatory power: The ability of the 2 techniques 
to distinguish between different confluence patterns and starting total RNA amounts based on the expression of individual genes was 
examined. All experiments were performed in triplicate. The numbers represent p values & values <0.05 (values in bold) are considered 
significant. Both StaRT PCR and Real Time PCR techniques have comparable power to discriminate between transcriptional status of 
cultures cells based on transcript quantification. As hypothesized, the differences in the starting RNA amount did not influence the 
transcript quantification.
Rb E2F p16 PCNA
StaRT PCR Real Time PCR StaRT PCR Real Time PCR StaRT PCR Real Time PCR StaRT PCR Real Time PCR
LD 419 Confluence 60% vs. 100% 0.019 0.33 0.36 0.31 0.62 0.21 <0.001 0.023
LD 419 Starting RNA amount 0.31 0.83 0.3 0.58 0.48 0.95 0.8 0.94
T24 Confluence 60% vs. 100% <0.001 0.4 0.18 0.024 0.061 0.99 0.73 0.86
T24 Starting RNA amount 0.03 0.63 0.34 0.52 0.15 0.34 0.12 0.53Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/5
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script quantification, which facilitates comparison of data
generated independently in different experiments, and
even in different labs [5]. Previous work with StaRT PCR
has showed sufficient evidence to establish that the native
as well as competitive templates amplify with the same
efficiency. Since the efficiency of amplification for the
native target and its competitor are identical, the ratio of
their amplification products is expected to be constant
and will reflect the initial transcript amounts [2]. We first
verified whether endogenous target and competitor
amplified at the same rate by following the NT/CT ratio
from cycle 23 to 35. Further, we verified the fidelity of this
amplification for different starting ratios of NT/CT over a
100-fold difference in the NT/CT ratio (0.1:1 to 10:1).
When the endogenous template and its competitor
existed at the same concentration (1:1) the CV across
cycles was seen to be less than 4%. In addition, the CV
between the calculated ACTB transcript numbers was
fairly low over a wide range of NT/CT ratios. This is of
interest since transcript quantification using this system is
invariably performed maintaining the NT/CT ratios as
close to 1:1 as possible. RB1, E2F1, PCNA and CDKN2A
were also tested for linearity of amplification and yielded
results similar to ACTB (CV <8 in all cases, data not
shown), thus validating the potential of this technology to
perform quantitative transcript measurement for any
selected panel of genes. However, the CV could not be cal-
culated for CDKN2A, where the low initial transcript
number precluded the possibility of measuring PCR prod-
ucts until cycle 32. Since StaRT PCR is a medium-high
throughput approach, transcript quantification will have
to be carried out in multiple tubes. Thus, the reaction
kinetics in multiple tubes must be comparable for reliable
transcript measurements obtained at the end of Start PCR
amplification. We have shown here that the inter-tube
variability between the rates of amplification is very low
and within the range of acceptable experimental noise,
increasing the confidence in absolute quantification of
gene transcripts by using this assay. This observation
augurs well for the use of StaRT PCR to perform medium-
high throughput transcript quantification.
Since many crucial cellular functions are regulated by only
minute changes in expression of certain genes, the effec-
tiveness of any transcript quantification technology
largely depends on its ability to detect such small varia-
tions in transcript expression (i. e., its sensitivity). As a
'proof of principle', we have shown that StaRT PCR is
capable of detecting as small as 7% change in endogenous
ACTB transcripts. Given the fact that transcript quantifica-
tion technology like cDNA microarray can detect, at best,
only a 40% change in transcript amount [6], the ability of
StaRT PCR is particularly striking. By virtue of its sensitiv-
ity in quantitative transcript measurement, StaRT PCR
technology has the potential to find application in a clin-
ical setting to improve diagnostic sensitivity and
specificity.
Comparison of StaRT PCR with the established real time
PCR assay for quantifying gene expression was carried out
to explore its feasibility as an inexpensive, standardized,
and equally sensitive alternative to the latter. The two
methods cannot be compared directly since they are based
on two different platforms. StaRT PCR relies on competi-
tion between endogenous and synthetic templates, while
the TaqMan real time PCR is based on specificity of probe-
amplicon hybridization where the fluorescent signal
reports quantitatively on formation of every new copy of
the template. Therefore, Spearman rank correlation test
was used to compare the transcript measurement by the
two methods, and the transcript estimation appears to be
concordant for each of the four genes.
Conclusion
In summary, StaRT PCR is a reliable and sensitive tech-
nique that can be applied to medium-high throughput
quantitative transcript measurement for biological and
clinical samples. Further, it correlates well with real time
PCR for its quantitative and discriminatory ability.
Though StaRT PCR is relatively more labor intensive, the
presence of internal standards in each PCR reaction con-
fers multiple advantages over real time RT-PCR.First, the
presence of competitive templates in each reaction mix
serves as the ideal internal standard to control for reaction
failure. Second, essentially similar reaction kinetics for
both native and competitive templates circumvents the
problems encountered in probe-based assays due to dif-
ferent hybridization efficiencies. Third, since transcript
measurements by StaRT PCR are numerical and standard-
ized, data generated in different labs can easily be com-
pared and they may be entered into a common gene
expression databank. Fourth, for any given cDNA sample,
correlation of transcript quantification is possible, facili-
tating the generation of a molecular signature. In addi-
tion, owing to lack of need for fluorescent label, it is much
less expensive making it more cost effective.
We have now extended the application of StaRT PCR to
simultaneously quantify as many as 72 genes in 8 bladder
cancer cell lines, as well as 100 frozen bladder cancer sam-
ples (manuscripts in preparation). Generation of molecu-
lar signatures unique to individual tumors and profiles for
genes across tumor samples will provide an additional
prognostic tool and help in identifying novel therapeutic
targets. Moreover, StaRT PCR offers the possibility of mul-
tiplex amplification of several genes in the same reaction
mix. Efforts in this direction have already yielded promis-
ing results [7]. Further, the StaRT PCR technology can be
combined with micro-fluidic electrophoresis and robotic
liquid handling, and such application has recentlyMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/5
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allowed expression measurement in a semi-automated
fashion [7].
Materials and Methods
Cell Culture
One human bladder transitional carcinoma cell line, T24
(ATCC, Manassas, VA, USA), and a normal fibroblastic
bladder primary culture cell line, LD 419 (developed and
kindly provided by Dr. P. Jones, University of Southern
California, USA), were grown in McCoys 5a medium (Inv-
itrogen, Carlsbad, CA, USA), with 10% FBS (CRL core
facility University of Southern California, USA). Cells
were harvested at approximately 60% and 100% conflu-
ence, and after cell count, each cell pellet was equally dis-
tributed into three aliquots of 107 cells. Thus, a total of 12
aliquots were prepared for RNA extraction from the two
cell types.
RNA Extraction and cDNA synthesis
RNA was extracted using the RNeasy midi kit from Qiagen
(Valencia, CA, USA) following the vendor's instructions.
For each of the two culture conditions, reverse transcrip-
tion was performed starting with 5 µg, 10 µg and 15 µg of
total RNA in triplicates, yielding a total of 36 samples for
the two cell lines. In each case, the cDNA preparation was
performed in a 50 µl reaction volume containing 200 U
Moloney Murine Leukemia Virus (MMLV) reverse tran-
scriptase, 2 mM dNTPs, 300 ng of random hexamers and
40 U of recombinant ribonuclease inhibitor in reverse
transcription buffer (50 mMTris-HCl, 75 mM KCl, 3 mM
MgCl2 and 2 mM dithioerythreitol). All reagents were
obtained from Invitrogen. The reaction was carried out for
1 h at 45°C, followed by reverse transcriptase inactivation
for 5 min. at 95°C.
StaRT PCR
A ready-to-use master mixture (MM containing Taq DNA
polymerase 1.25 units, dNTPs 0.2 mM each, reaction
buffer, 1.5 mM MgCl2, gel loading dye and precipitant)
(1.1 X ReddyMix, Cat # AB-0575 LD/C, Abgene, Epsom
U.K.) was used to reduce risk of contamination and pipet-
ting errors. StaRT PCR was performed using internal
standard competitive template (CT) mixtures (A-F) from
Gene Express, Inc. (Toledo, OH). While each of the six
mixtures (A-F) contained internal standard CTs for 381
"target" genes, our pilot study targeted RB, E2F1,
CDKN2A and PCNA genes. The concentration of β-actin
(ACTB) internal standard CT was 10-12 M (6 × 105 mole-
cules/l) in each mix, while the concentration of the inter-
nal standards for the "target" genes varied serially 10 fold
Determination of an Equivalence Point (EP) in bladder cell lines LD419 and T24 Figure 3
Determination of an Equivalence Point (EP) in bladder cell lines LD419 and T24: Equivalence point for any sample 
is defined as the concentration of cDNA, which yields a visually equivalent band intensity between the NT & CT (1:1 ratio) for 
ACTB. cDNA dilution approximating the equivalence point is chosen for further quantification experiments. Decreasing con-
centrations of cDNA (NT) were separately added to a constant volume of CT mix (containing ACTB competitor at 10-12M), 
and the mixtures were amplified using ACTB primers for 35 cycles. The PCR products were electrophoresed and the 'equiva-
lence points' were visually assigned for LD419 and T24 cDNA (arrows).Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/5
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from 10-11M in Mix A through 10-16 M in Mix F. This ena-
bled the quantification of the target transcripts across 6
logs of concentrations. Since every CT mix contained
ACTB CT molecules at 10-12 M concentration, 1 µl was
equivalent to 6 × 105 molecules. Normalization of the test
sample was performed to identify the concentration of the
test cDNA sample where the ACTB transcripts existed at 6
× 105 molecules. To achieve this, serial dilutions of a
cDNA sample were mixed with a constant amount (1 µl)
of ACTB competitor contained in one of the CT mixes. A
typical 50 µl PCR reaction contained 1 µl of CT mix, 1 µl
of test cDNA sample containing native template (NT), 0.5
µl of each of the ACTB primers and 47 µl of MM. Follow-
ing gel electrophoresis of the PCR products, the concen-
tration of the test cDNA sample at which the band
intensities of the NT was visually equivalent to that of the
CT was designated as the 'equivalence point'. For any test
sample, the cDNA concentration close to the equivalence
point was chosen to proceed for further quantification
experiments (figure 3). Thus, for each sample a master
mix containing the CT mix and the cDNA sufficient for
expression measurements of the five genes (cell cycle spe-
cific genes, and ACTB) were prepared and aliquoted into
five tubes containing the respective primers. The proce-
dure was repeated for each of the CT mixes. Normaliza-
tion and quantification reactions were carried out in a
PTC-100 thermal cycler (MJ research, Waltham MA, USA)
for 35 cycles, with the following thermal profile: initial
denaturation step-95° C, 5 minutes, followed by 35 cycles
of denaturation at 94° C, 1 minute annealing at 58° C, 1
minute, extension at 72° C, 1 minute. A final 10-minute
extension at 72°C was followed by a 4°C soak until the
samples were used for gel electrophoretic analysis. The
primers and the internal sequences used to generate the
CT are listed in table 5.
Data Analysis and quantitation
Following PCR, amplification products were electro-
phoresed in a 3% SeaKem agarose gel (BMA, Rockland,
ME, USA), using a 104 lane high-throughput
electrophoresis system (CBS, Del Mar, CA, USA, cat# SGU
2640T-02), and stained with 0.05 µg/ml ethidium bro-
mide. A computer-integrated system comprising Fluor-S-
MultiImager Hardware and Quantity One software (Bio-
Rad, Hercules, CA, USA) was used for digital acquisition
of gel images and for quantification of the band fluores-
cence intensities.
In all cases, band intensity was expressed as volume under
the curve: pixel intensity × mm2. Determination of the
number of molecules present in each band has been
described [2]. NT pixel intensity was corrected taking into
account the size difference between NT and CT (corrected
NT pixel intensity=observed NT pixel intensity × NT size /
CT size). A third band corresponding to the hetero-duplex
was often observed between NT and CT. Since hetero-
duplex formation disturbs the final homo-duplex product
ratios, it was essential that hetero-duplexes were identi-
fied, accurately quantified and their contribution to final
product ratios included in the analysis [3]. Hence, we
attributed half the pixel intensity of each hetero-duplex to
the corrected NT pixel intensity and the other half to the
CT pixel intensity. The initial number of cDNA (NT) mol-
ecules was then calculated as [(corr. NT pixel intensity /
Table 5: Primers and probes used for real-time PCR analysis for 5 target genes
Gene Forward Primer Reverse Primer Probe
ACTB TGAGCGCGGCTACAGCTT CCTTAATGTCACACACGATT 6FAM5'-ACCACCACGGCCGAGCGG-3'TAMRA
PCNA CTGCAGAGCATGGACTCGTC GTAGGTGTCGAAGCCCTCAGA 6FAM5'-ACGTCTCTTTGGTGCAGCTCACCCTG-3'TAMRA
CDKN2A CATAGATGCCGCGGAAGGT CCGGAGGTTTCTCAGAGCCT 6FAM5'-CCTCAGACATCCCCGATTGAAAGAACC-3'TAMRA
E2F1 GAACTGAGGCCTGGGTGATTT CCACCCATGGCTGTCAGTC 6FAM5'-TCTGTCTCCCTCCCTCACTTTCCCAATAA-
3'TAMRA
RB1 TTCCAGAAAATAAATCAGATGGTATGTAA CAGTGGTTTAGGAGGGTTGCTT 6FAM5'-CAGCACTTCTTTTGAGCACACGGTCG-3'TAMRA
Primers used for StaRT PCR analysis for 5 target genes
Gene Forward primer Reverse Primer for NT Reverse Primer for CT
ACTB GATTCCTATGTGGGCGACGAG CCATCTCTTGCTCGAAGTCC CCATCTCTTGCTCGAAGTCCCCATCTCTTGCTCGAAGTC
CGCCAGCCAGGTCCAGACGCA
CDKN2A GGAGCCCAACTGCGCCGACC CCTTCGGTGACTGATGATCTAA CCTTCGGTGACTGATGATCTAAGGAGCCCAACTGCGCC
GACCCCCGTGGACCTGGCTGAG
E2F1 TGATACCCCAACTCCCTCTA AAAGCAGGAGGGAACAGAGC AAAGCAGGAGGGAACAGAGCAAAGCAGGAGGGAACAG
AGCACTGCAGGGACCACAGG
PCNA GCTCCAGCGGTGTAAACCTGCA CGTGCAAATTCACCAGAAGGCA CGTGCAAATTCACCAGAAGGCACGTGCAAATTCACCAG
AAGGCATCAACTTCATTTCATAGTCTGA
RB1 TTTCAGAAGGTCTGCCAACACCAA GTGTCCACCAAGGTCCTGAGATCC GTGTCCACCAAGGTCCTGAGATCCGTGTCCACCAAGGT
CCTGAGATCCCATTTCTGCCAGTTTCTGCTGAAAMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/5
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CT pixel intensity) × CT molecules]. For every target gene,
ACTB transcripts were also measured for standardization
of the results, and for each gene the number of transcripts
was expressed as number of copies per 106  ACTB
molecules.
Testing Linearity of StaRT PCR amplification
The Start PCR system uses end point analysis to quantify
the initial number of transcripts of a particular gene in a
given sample. As described above, the relative band inten-
sities of the NT, CT and HD following StaRT PCR amplifi-
cation and gel electrophoretic analysis are assessed and
used to calculate the initial transcript number in the NT.
Therefore, we investigated:
a) The linearity of Standardized Competitive RT-PCR
(StaRT PCR) amplification system
b) Coefficients of Variation (CV) between the initial ACTB
transcript numbers in the NT for each of the designed NT/
CT ratios.
The linearity of Start PCR amplification was tested as fol-
lows: LD419 cell line was used to quantify the native
(endogenous) ACTB transcripts by measuring the NT/CT
ratios at cycle numbers 23, 26, 29, 32 & 35. LD419 cDNA
was mixed with the CT to arrive at NT/CT ratios of 0.1, 0.5,
1, 5, and 10. Independently, each of these 5 initial NT/CT
ratios were used to set up separate reactions, which were
then subjected to PCR amplification and terminated at
cycles 23, 26, 29, 32, 35. All experiments were performed
in triplicate. The mean observed NT/CT ratios (following
quantification using BioRad Quantity One software) at
each end point were plotted against the cycle numbers at
which the reactions were terminated. Similar analysis was
performed for each of the other four genes, RB1, E2F1,
CDKN2A, and PCNA, at the same NT/CT ratios, following
empirical determination of the appropriate CT mix (from
among A-F) for respective genes.
Further, using replicate experiments, coefficients of varia-
tion (CV) were calculated between the initial ACTB tran-
script numbers in the NT obtained based on the observed
NT/CT ratios at the end of StaRT PCR amplification for
each of the designed NT/CT ratios.
Testing Inter-tube variability in StaRT PCR amplification
Since expression profiling and signature generation stud-
ies for clinical cDNA samples using gene panels would be
done using separate reaction tubes, we compared the var-
iability in transcript quantification between multiple
tubes subjected simultaneously to the StaRT PCR amplifi-
cation system. In this experiment to test the inter sample
variability, we quantified the number of native ACTB tran-
scripts for the in LD419 cell line. We used NT/CT ratio of
1:1 based on our results of the CV calculation described
above. Equal inputs of cDNA for ACTB transcripts were
amplified in multiple tubes simultaneously and the PCR
reactions terminated at cycles 20, 23, 26, 29, 32 & 35.
Experiments were performed in triplicate. The ACTB tran-
scripts in each of the tubes were quantified at the desig-
nated end points and the variability between the values
obtained from the multiple tubes compared.
Determination of Sensitivity of StaRT PCR in detecting 
small changes in transcript amount
The effectiveness of any quantitative technology for gene
expression depends to a large measure on its sensitivity to
detect small differences in values for individual samples,
since many crucial cellular functions are regulated by
minute changes in gene expression. NT/CT ratios were
therefore designed to test the ability of StaRT PCR to
detect minute changes in transcript quantity. LD419 and
T24 cDNAs were normalized using ACTB primers (figure
3). In each case, NT volumes decreasing successively by
0.4 µL were mixed with a constant volume of CT (4 µL of
10-12M ACTB) to obtain NT/CT dilutions over a range of
1.5:1 to 0.5:1. This allowed us to test the sensitivity of
StaRT PCR over a demanding range of expression changes
from 6%-15%. The starting cDNA concentrations used for
this experiment were visually determined to be different
for T24 and LD419; cDNA volume for T24 chosen was the
one that yielded the equivalence point, while that for
LD419 was approximately 1.5 times the one required for
equivalence point. These different cDNA volumes were
deliberately chosen to examine the consistency of tran-
script quantification over equal successive decrease in
ACTB transcript number for the two cell lines (6%-15%),
in spite of the differences in starting transcript numbers.
These reaction mixes were then subjected to StaRT PCR
amplification using ACTB primers and the corresponding
number of ACTB transcripts in the NT was calculated. All
experiments were performed in triplicate. The mean abso-
lute numbers of ACTB transcripts quantified from each
NT/CT titration were plotted against the NT/CT ratio.
Comparison of StaRT PCR with real time PCR
In order to compare the transcript quantification by StaRT
PCR and real time PCR, T24 and LD419 cells were grown
to two different confluence conditions, 60% and 100%,
and harvested to extract total RNA. From each of these
total RNA extracts, RNA amounts equivalent to 5, 10 & 15
µg were reverse transcribed in triplicates to obtain a total
of 36 cDNA preparations. ACTB, RB1, E2F1, CDKN2A and
PCNA transcripts were subsequently quantified from each
cDNA preparation using StaRT PCR and real time PCR.
Real time PCR primers and probes design
The quantification of mRNA was carried out using a real
time fluorescence detection method essentially asPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/5
Page 11 of 11
(page number not for citation purposes)
described. Briefly, each of the cDNAs of interest was PCR-
amplified using unlabeled primers in presence of a gene
specific oligonucleotide probe with a 5' fluorescent
reporter dye (6FAM) and a 3' quencher dye (TAMRA).
During each primer extension step, the 5' to 3' exonucle-
ase activity of Taq DNA polymerase cleaves the annealed
probe and releases the fluorescent reporter away from the
quencher moiety, resulting in a fluorescent signal, which
was then detected using a suitable detector system (ABI
Prism 7700 Sequence Detection System, (Perkin-Elmer,
Foster City, CA). Initial template concentration was
derived from the cycle number at which the fluorescent
signal crosses a threshold in the exponential phase of the
PCR reaction. Relative gene expression was determined
based on the threshold cycles (Ct values) of the gene of
interest (RB1, CDKN2A (p16), PCNA and E2F1) and of
the internal reference gene (ACTB). The PCR amplifica-
tion was performed using a 96-well optical tray and caps
with a final reaction mixture of 30 ml which consisted of
300 nM of each primer, 100 nM probe, 0.5 U Ampli-Taq
Gold, 240 mM each of dATP, dCTP, dGTP, TTP, 3.5 mM
MgCl2, and 1× TaqMan Buffer A containing a reference
dye at the following conditions: 95°C for 10 min, fol-
lowed by 40 cycles at 95°C for 15 s and 60°C for 1 min.
The primer and probe sequences are listed in table 5.
Statistical Analysis
All statistical calculations were performed using SAS soft-
ware. Relevant tests are described under the respective sec-
tions below.
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